Sector News

Onwards! Novo Nordisk’s once-weekly insulin marches on after hitting goals in pair of phase 3 trials

July 31, 2022
Life sciences

Novo Nordisk has added more threads to the data tapestry it is weaving in support of the once-weekly insulin icodec, dropping positive top-line results from two phase 3a studies in its six-part ONWARDS program.

The Danish drugmaker posted data from ONWARDS 1, 2 and 6 earlier this year. All three studies hit their primary endpoints, raising hopes that insulin icodec can address some of the issues associated with the use of once-daily basal insulin analogs such as Novo’s own Tresiba. In theory, reducing the frequency of dosing could improve convenience, adherence, quality of life and, by extension, glycemic control.

Novo released top-line data from two more insulin icodec studies, ONWARDS 3 and 4, on Friday. Like the other ONWARDS trials, the two studies met their primary endpoints by achieving noninferiority to active controls.

Tresiba was the control in ONWARDS 3, which enrolled 588 insulin-naïve people with Type 2 diabetes. After 26 weeks of treatment, hemoglobin A1c, a measure of blood sugar, had fallen 1.57% from a baseline of 8.5% in the insulin icodec cohort, compared to a 1.36% reduction in the control group. Novo saw no statistically significant difference in severe or clinically significant hypoglycemia, although the rate was numerically higher in the insulin icodec group. The firm said the drug appeared safe and well tolerated.

ONWARDS 4 looked at basal-bolus treatment in people with Type 2 diabetes, pitting insulin icodec against insulin glargine, sold by Sanofi as Lantus. After 26 weeks, hemoglobin A1c had fallen 1.16% from a baseline of 8.3% in the insulin icodec cohort, compared to a 1.18% reduction in the control group. Again, Novo saw no statistically significant difference in severe or clinically significant hypoglycemia.

“We are very pleased to see that the results from ONWARDS 3 and 4 reinforce the potential of once-weekly insulin icodec to simplify basal insulin therapy for people with type 2 diabetes as an ideal starter insulin and as an attractive option in combination with mealtime insulin,” Martin Holst Lange, executive vice president for development at Novo, said in a statement.

Novo now has data from five of the six clinical trials in its phase 3 ONWARDS program. Top-line results from the remaining study, ONWARDS 5, are due by the end of the year.

By Nick Paul Taylor


comments closed

Related News

August 7, 2022

Amid Wegovy’s supply woes, Novo Nordisk sees surging demand for its original obesity drug Saxenda

Life sciences

After a contract manufacturing snafu in December, supply of Novo Nordisk’s GLP-1 med for obesity appears to be back on track in the U.S.—mostly. Novo’s Wegovy manufacturing partner—which the Danish company previously confirmed to Fierce Pharma as Catalent—restarted production on the med in 2022’s second quarter. As a result, 1.7-mg and 2.4-mg doses of Wegovy are back on tap in the U.S. market, Novo said in a recent investor report.

August 7, 2022

After delay, CSL’s $11.7B deal for Vifor poised to close next week

Life sciences

Once the offer is settled, CSL expects to get its hands on more than 97% of Vifor shares. At the same time, CSL plans to have Vifor apply for the delisting of its shares post-close. CSL has also filed an action to cancel remaining publicly held Vifor shares to satisfy Swiss takeover rules.

August 7, 2022

Amgen to acquire biopharma firm ChemoCentryx for $3.7bn

Life sciences

Amgen has signed a definitive agreement to acquire biopharmaceutical company ChemoCentryx for $52 for each share in cash or a total enterprise cost of nearly $3.7bn. ChemoCentryx focuses on orally administered therapeutics for the treatment of inflammatory disorders, autoimmune ailments and cancer.